News
  • Discover
  • Journals
  • Momentum
  • Rankings
  • Local
  • Trending
  • Latest
  • Top Stories
  • Rising
  • Controversial
  • Bubble Gap
  • Log in

Get above the noise

Log in for answers tailored to you — saved chats, your topics, and the full IJR suite.

Log in

IJR News

© IJR AI, Inc.

Privacy PolicyTerms of UseCookie PolicyInvestorsGet the appContact
what's gaining coverage right now
🕹️ Today in the ArcadeLiving Light · ⚡ Night ShiftPlay →✍️ Voices risingRand Paul Introduces Resolution To Hold Fauci In Contempt · Daily Caller News Foundation · most read this weekRead →
Huicheng District Sends 26 Firms to Canton Fair

Huicheng District Sends 26 Firms to Canton Fair

The 139th Canton Fair in Guangzhou ran April 15–May 5 in three phases, with 26 Huicheng District enterprises occupying 38 booths; 11 firms debuted in the first phase, including Wandisplay Technology and Saiweier Electric Appliances, and 15 more participated in the later phases with products from smart wearables to LCD displays. Preparations included Mobilization Meetings and Policy Promotion Training by the Huicheng District Bureau and the Municipal Bureau of Commerce on March 26 and April 2 to clarify booth regulations, penalties, and exhibitor certificate applications to improve participation effectiveness.

📍People's Republic of China🏢Canton Fair
Jul 24, 2026
EU Approves Etcamah in First-Line ER+ Breast CancerEuropean Union

EU Approves Etcamah in First-Line ER+ Breast Cancer

AstraZeneca’s Etcamah (camizestrant) won EU approval to be used with CDK4/6 inhibitors as a first-line treatment for ER-positive, HER2-negative advanced breast cancer in patients with ESR1 mutations, based on SERENA-6 trial results showing a 56% reduction in progression or death. The drug already has approvals in Japan, the UAE, and Saudi Arabia, with U.S. review ongoing and the EU decision highlighting its potential to expand AstraZeneca’s oncology footprint as it targets endocrine-resistant disease.

📍United States🏢European Union
Jul 23, 2026
Crystalys Therapeutics raises $130M Series BStartups

Crystalys Therapeutics raises $130M Series B

Crystalys Therapeutics has raised a $130 million Series B led by Frazier Life Sciences with participation from multiple investors to fund late-stage global trials and commercialization plans for dotinurad, its URAT1 inhibitor for gout. The financing backs the RUBY, TOPAZ, and AMETHYST studies and aims to accelerate regulatory milestones and commercial readiness across the U.S. and Europe as the company positions dotinurad as a best-in-class option between first-line therapies and last-line treatments.

📍United States📍Europe
Jul 22, 2026
From IJR journals·Daily Caller News FoundationPreemptive Request: Zero Government Bailouts For AI Fails, PleaseThe U.S.’s Artificial Intelligence (AI) self-feeding frenzy is still … frenzy-ing. The U.S.’s Artificial Intelligence (AI) self-feeding frenzy is still … frenzy-ing. Except everything about it seems fake. The U.S.’s Large Language Model (LLM) version of AI seems to be (at least) years away from the promises being made to feed the frenzy. Which can be seen as a partially good thing — since no one has any idea what to do with the hundreds of millions of humans they tell us U.S. AIAug 4

More headlines

  • Group One Trading trims KRE, boosts BITO, SBITGroup One Trading LLC trimmed its SPDR S&P Regional Banking ETF stake by 23.4% in Q1 to 55,805 shares, while dramatically increasing its ProShares Ultra Short Bitcoin ETF position by 4,555.3% to 10,940 shares and boosting its ProShares Bitcoin ETF holding by 14.2% to 460,289 shares. The firm also reduced its ProShares Ultra Silver stake by 24.6% to 67,835 shares.6 src · Jul 23, 2026
  • Man Opens Police Van Latch, Protesters EscapeA viral video shows a man opening the latch of a police van in Chembur, Mumbai, allowing several detained student protesters from a 700–800-strong rally to escape as police had restrained and later detained around 200 individuals. The incident, which prompted widespread debate over police conduct and featured multiple videos of protesters and slogans, coincides with 13 cases and about 400 people booked for unlawful assembly and violation of prohibitory orders.8 src · Jul 23, 2026
  • GSK earns FDA approval for JideytroGSK won FDA approval for Jideytro (zidesamtinib), its ROS1 inhibitor for ROS1-positive non-small cell lung cancer, ahead of the September 18 deadline as part of its Nuvalent acquisition. The treatment, showing a 44% response rate in trials, positions GSK to compete in lung cancer and supports ongoing development of additional Nuvalent assets like neladalkib and ris-rez.9 src · Jul 23, 2026